Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.

Accurso, V., Santoro, M., Mancuso, S., Napolitano, M., Di Piazza, F., Russo, A., et al. (2019). Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. DRUGS IN CONTEXT, 8 [10.7573/dic.212569].

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

Santoro, Marco;Mancuso, Salvatrice;Napolitano, Mariasanta;Di Piazza, Florinda;Russo, Antonio;Siragusa, Sergio
2019

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.
https://drugsincontext.com/efficacy-of-ruxolitinib-retreatment-in-a-patient-with-high-risk-myelofibrosis-using-the-international-prognostic-scoring-system
Accurso, V., Santoro, M., Mancuso, S., Napolitano, M., Di Piazza, F., Russo, A., et al. (2019). Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. DRUGS IN CONTEXT, 8 [10.7573/dic.212569].
File in questo prodotto:
File Dimensione Formato  
Articolo Ruxo.pdf

accesso aperto

Dimensione 221.23 kB
Formato Adobe PDF
221.23 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/350127
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact